Immunic Plunges 16.41% on Disappointing Trial Data

On April 30, 2025, Immunic's stock experienced a significant drop of 16.41% in pre-market trading.

The decline in Immunic's stock price can be attributed to the release of Phase 2 trial data for its lead candidate, vidofludimus calcium, which is targeted at multiple sclerosis. The data indicated that the drug did not meet the primary endpoint, leading to a substantial decrease in investor confidence.

Further analyses by disease subtype showed that vidofludimus calcium was associated with a 30% reduction in the relative risk of 24-week confirmed disability worsening events. However, this positive finding was not sufficient to offset the overall disappointing results from the trial.

Immunic's short interest ratio and volume data also played a role in the stock's decline. With a short interest of 2.07 million shares, representing 2.37% of the float, the market sentiment was already bearish before the trial results were announced.